Prevention of Cardiovascular Events: VYTORIN is indicated to reduce the risk of cardiovascular events (see Pharmacology: Pharmacodynamics under Actions) in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS), either previously treated with a statin or not.
Hypercholesterolaemia: VYTORIN is indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate: patients not appropriately controlled with a statin alone; patients already treated with a statin and ezetimibe.
Homozygous Familial Hypercholesterolaemia (HoFH): VYTORIN is indicated as adjunctive therapy to diet for use in patients with HoFH. Patients may also receive adjunctive treatments (e.g., low-density lipoprotein [LDL] apheresis).